Mark D. Vincent - 18 Jan 2022 Form 4 Insider Report for Aptose Biosciences Inc. (APTOF)

Role
Director
Signature
/s/ Janet Clennett as attorney-in-fact for Mark D. Vincent
Issuer symbol
APTOF
Transactions as of
18 Jan 2022
Net transactions value
$0
Form type
4
Filing time
20 Jan 2022, 16:15:39 UTC
Next filing
23 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APTO Director Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 18 Jan 2022 Common Shares 50,000 $1.39 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Converted from Canadian exercise price of C$1.74 using an exchange rate of C$1.2529 = US$1.00.
F2 The options were granted on January 18, 2022, and vest as follows: 50% vest on January 18, 2023; 25% vest on January 18, 2024; and 25% vest on January 18, 2025.